|
Online Database of Chemicals from Around the World | 产品搜索 | 产品提交 | 产品推广 |
网站主页 >> 化工产品目录 >> 莫特塞尼>> 市场分析报告 |
莫特塞尼市场分析报告 |
|
Motesanib (CAS 453562-69-1) Market Research Report 2025 BAC Reports offers its clients in-depth market research of chemical industry products on the global and regional markets (North & Latin America, Asia Pacific, European Union, Russia and CIS). Motesanib Market Research Report 2025 BAC Reports offers its clients in-depth market research of chemical industry products on the global and regional markets (North & Latin America, Asia Pacific, European Union, Russia and CIS). Global Market Report of Motesanib (CAS 453562-69-1) December 2024 Global Market Report of Motesanib (CAS 453562-69-1) December 2024 Global Market Report of Motesanib diphosphate (CAS 857876-30-3) December 2024 CAS 453562-69-1 Motesanib Chemical Report & Database ... listed. The substance covered (Motesanib) are classified by the Chemical ... Report & Database definitions: Name: Motesanib: Motesanib; AMG 706; N-(2,3-Dihydro-3,3-dimethyl-1H- ... : Chemical or Reaction Intermediate The Motesanib Report & Database gives Market ... CAS 857876-30-3 Motesanib diphosphate Chemical Report & Database ... Report & Database This Motesanib diphosphate Chemical World Consumption ... & Database definitions: Name: Motesanib diphosphate: Motesanib-diphosphate; N-(2,3-Dihydro-3,3-dimethyl ... or Reaction Intermediate The Motesanib diphosphate Report & Database gives ... Small Molecule Kinase Inhibitors: Market Research Report This report analyzes the Global Market for Small Molecule Kinase Inhibitors in Millions of US$ by the following Product Segments: Gleevec/Glivec, Tarceva, Sutent, Nexavar, Sprycel, Iressa, Tykerb/Tyverb, and Others. Annual forecasts are provided for the ... Conference Intelligence Dossier: ECCO 15 - ESMO 34 Congress, 2009 Every year, the numbers grow exponentially: 10.9 million new cancer diagnoses worldwide, 6.7 million cancer deaths annually. But as the number of cases expand, so, too, does the number of five-year survivors—and the amount of groundbreaking oncology ... |